Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

NCT03208556 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory B-cell Lymphoma

Interventions

BIOLOGICAL: iPD1 CD19 eCAR T cells
DRUG: Fludarabine and cyclophosphamide

Sponsor

Peking University

Collaborators

[object Object]